Benitec Biopharma Inc
BNTC11.620USD
+0.660+6.02%
收盘 08/04, 16:00（美东）报价延迟15分钟
296.85M总市值
亏损市盈率 TTM
关于 Benitec Biopharma Inc 公司
Benitec Biopharma Inc 是一家临床阶段的生物技术公司。该公司专注于新型基因药物的开发。其专有的 Silence and Replace 脱氧核糖核酸 (DNA) 定向核糖核酸 (RNA) 干扰平台将 RNA 干扰 (RNAi) 与基因疗法相结合，创造出在单次施用治疗构建体后同时促进致病基因持续沉默和野生型替代基因同时递送的药物。该公司正在开发基于 Silence and Replace 的疗法 (BB-301)，用于治疗包括眼咽型肌营养不良症 (OPMD) 在内的慢性和危及生命的人类疾病。BB-301 是一种基于腺相关病毒载体 (AAV) 的基因疗法，旨在抑制致病基因的表达（减缓或停止疾病进展的潜在机制）并同时用正常的野生型基因替换突变基因。
公司简介
公司代码BNTC
公司名称Benitec Biopharma Inc
上市日期Jul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
员工数量16
证券类型Ordinary Share
年结日Jul 11
公司地址3940 Trust Way
城市HAYWARD
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94545
电话15107800819
网址https://benitec.com/
公司代码BNTC
上市日期Jul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Mr. J. Kevin Buchi, CPA
Mr. J. Kevin Buchi, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2023
FY2022
FY2021
FY2019
业务USD
名称
营收
占比
Licensing revenue
75.00K
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Licensing revenue
75.00K
0.00%
股东统计
更新时间: 5月23日 周五
更新时间: 5月23日 周五
持股股东
股东类型
持股股东
持股股东
占比
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
持股股东
持股股东
占比
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
股东类型
持股股东
占比
Hedge Fund
51.24%
Investment Advisor/Hedge Fund
24.03%
Investment Advisor
9.80%
Corporation
2.84%
Research Firm
0.33%
Individual Investor
0.27%
Other
11.48%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
68
23.23M
88.49%
+3.01M
2025Q1
66
23.17M
88.28%
+2.93M
2024Q4
60
20.95M
89.36%
+4.31M
2024Q3
56
15.45M
85.62%
+7.92M
2024Q2
55
8.11M
85.06%
+2.49M
2024Q1
53
1.49M
56.66%
-268.80K
2023Q4
54
1.42M
56.57%
-342.85K
2023Q3
57
1.50M
61.34%
-154.56K
2023Q2
56
827.91K
52.26%
-194.13K
2023Q1
56
861.88K
54.33%
-200.92K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Suvretta Capital Management, LLC
9.88M
37.62%
+916.50K
+10.23%
Mar 31, 2025
Janus Henderson Investors
2.92M
11.12%
+302.52K
+11.56%
Mar 31, 2025
Franklin Advisers, Inc.
2.86M
10.9%
-78.56K
-2.67%
Mar 31, 2025
Adage Capital Management, L.P.
1.97M
7.51%
--
--
Mar 31, 2025
HBM Partners AG
1.04M
3.97%
+200.27K
+23.80%
Dec 31, 2024
Nantahala Capital Management, LLC
838.10K
3.19%
--
--
Mar 31, 2025
Nemean Asset Management, LLC
746.32K
2.84%
+648.12K
+659.98%
Apr 22, 2024
INFINITUM ASSET MANAGEMENT, LLC
475.00K
1.81%
+265.00K
+126.19%
Mar 31, 2025
The Vanguard Group, Inc.
327.03K
1.25%
+27.01K
+9.00%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
261.76K
1%
+1.35K
+0.52%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Health Care ETF
0.62%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 ETF
0%
Simplify Health Care ETF
占比0.62%
iShares Micro-Cap ETF
占比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
iShares Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
公告日期
类型
比率
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
